1
|
Sun M, Zhao Y, Han M, Zhang B, Zhang X, Zhang Q, Lim NKH, Wang WA, Huang FD. TTC7 and Hyccin Regulate Neuronal Aβ42 Accumulation and its Associated Neural Deficits in Aβ42-Expressing Drosophila. J Alzheimers Dis 2018; 65:1001-1010. [PMID: 30103315 DOI: 10.3233/jad-170907] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Neuronal amyloid-β (Aβ) accumulation plays an important role in the pathogenesis of Alzheimer's disease (AD). The conformation and toxicity of Aβ are regulated by lipids on the plasma membrane. Previously, we found downregulation of Rolling Blackout (RBO) or phosphatidylinositol-4-kinase type IIIα (PI4KIIIα) reduces neuronal Aβ accumulation and associated neural deficits in a Drosophila model expressing Aβ42. In mammals, the homologs of RBO and PI4KIIIα were reported to form a plasma membrane-localized complex with a scaffold protein TTC7 and cytosolic protein Hyccin/FAM126A to tightly control the plasmalemmal level of phosphatidylinositol-4-phosphate. Here, we show genetic downregulation of Drosophila TTC7 and Hyccin also reduces neuronal Aβ accumulation and associated synaptic and motor defects as well as premature death in Aβ42-expressing flies, while overexpression of TTC7 and Hyccin produced the opposite effect. These results, together with our previous study, demonstrate that RBO/TTC7/PI4KIIIα/Hyccin regulate neuronal Aβ accumulation and associated neural deficits in the Drosophila model, further supporting the RBO/Efr3-PI4KIIIα complex as a potential therapeutic target for AD.
Collapse
Affiliation(s)
- Minghao Sun
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Yinghui Zhao
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.,Laboratory of Molecular Neurobiology, School of Life Sciences, Shanghai University, Shanghai, China
| | - Men Han
- Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China
| | - Baozhu Zhang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Xiao Zhang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Qichao Zhang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.,Sino-Danish College, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing, China
| | - Nastasia K-H Lim
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.,Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
| | - Wen-An Wang
- Department of Neurology, Xinhua Hospital Chongming Branch Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Fu-De Huang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.,Sino-Danish College, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
2
|
Abstract
The cerebrospinal fluid (CSF) is a valuable body fluid for analysis in neuroscience research. It is one of the fluids in closest contact with the central nervous system and thus, can be used to analyze the diseased state of the brain or spinal cord without directly accessing these tissues. However, in mice it is difficult to obtain from the cisterna magna due to its closeness to blood vessels, which often contaminate samples. The area for CSF collection in mice is also difficult to dissect to and often only small samples are obtained (maximum of 5-7 µL or less). This protocol describes in detail a technique that improves on current methods of collection to minimize contamination from blood and allow for the abundant collection of CSF (on average 10-15 µL can be collected). This technique can be used with other dissection methods for tissue collection from mice, as it does not impact any tissues during CSF extraction. Thus, the brain and spinal cord are not affected with this technique and remain intact. With greater CSF sample collection and purity, more analyses can be used with this fluid to further aid neuroscience research and better understand diseases affecting the brain and spinal cord.
Collapse
Affiliation(s)
- Nastasia K-H Lim
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Science; Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Chinese Academy of Science;
| | - Visse Moestrup
- Center of Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University; Sino-Danish Center for Education and Research (SDC)
| | - Xiao Zhang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Science
| | - Wen-An Wang
- Department of Neurology, Xinhua Hospital Chongming Branch Affiliated to Shanghai Jiao Tong University School of Medicine
| | - Arne Møller
- Center of Functionally Integrative Neuroscience, Department of Clinical Medicine, Aarhus University; Sino-Danish Center for Education and Research (SDC); Department of Nuclear Medicine and PET-centre, Aarhus University Hospital
| | - Fu-De Huang
- Shanghai Advanced Research Institute, University of Chinese Academy of Sciences, Chinese Academy of Science; Sino-Danish Center for Education and Research (SDC);
| |
Collapse
|
3
|
Lim NKH, Villemagne VL, Soon CPW, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX. Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. J Alzheimers Dis 2012; 26:779-86. [PMID: 21694463 DOI: 10.3233/jad-2011-101974] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Pathological changes in the Alzheimer's disease (AD) brain include amyoid-β (Aβ) plaques, and neurofibrillary tangles, as well as neuronal death and synaptic loss. Matrix metalloproteinases MMP-2 and MMP-9 are known to degrade Aβ, and their expressions are increased in the AD brain, in particular in the astrocytes surrounding amyloid plaque. To investigate a possible association between plasma metalloproteinases and AD, we quantified MMP-2 and MMP-9 activities in the plasma of healthy controls (HC, n = 56), cases with mild cognitive impairment (MCI, n = 45), and AD (n = 50). All cases had previously been imaged with Pittsburgh compound B (PiB) and had a Mini-Mental Status Examination (MMSE) assessment. MMP-2 and MMP-9 activity was determined using gelatine-zymography. There was a significant 1.5-fold decrease in MMP-2 activity in the AD group compared to HC (p < 0.001) and a 1.4-fold decrease compared to MCI (p < 0.01). There was no difference in MMP-9 levels between the three groups. A positive correlation was identified between MMP-2 plasma activity and MMSE score (r = 0.16, p < 0.05), but there was no association with PiB. This is the first report of a change in MMP-2 activity in AD plasma and these findings may provide some insight into AD pathogenesis.
Collapse
Affiliation(s)
- Nastasia K-H Lim
- Department of Pathology, The University of Melbourne, Parkville Vic, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Soon CPW, Donnelly PS, Turner BJ, Hung LW, Crouch PJ, Sherratt NA, Tan JL, Lim NKH, Lam L, Bica L, Lim S, Hickey JL, Morizzi J, Powell A, Finkelstein DI, Culvenor JG, Masters CL, Duce J, White AR, Barnham KJ, Li QX. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem 2011; 286:44035-44044. [PMID: 22033929 DOI: 10.1074/jbc.m111.274407] [Citation(s) in RCA: 109] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive paralyzing disease characterized by tissue oxidative damage and motor neuron degeneration. This study investigated the in vivo effect of diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)), which is an orally bioavailable, blood-brain barrier-permeable complex. In vitro the compound inhibits the action of peroxynitrite on Cu,Zn-superoxide dismutase (SOD1) and subsequent nitration of cellular proteins. Oral treatment of transgenic SOD1G93A mice with CuII(atsm) at presymptomatic and symptomatic ages was performed. The mice were examined for improvement in lifespan and motor function, as well as histological and biochemical changes to key disease markers. Systemic treatment of SOD1G93A mice significantly delayed onset of paralysis and prolonged lifespan, even when administered to symptomatic animals. Consistent with the properties of this compound, treated mice had reduced protein nitration and carbonylation, as well as increased antioxidant activity in spinal cord. Treatment also significantly preserved motor neurons and attenuated astrocyte and microglial activation in mice. Furthermore, CuII(atsm) prevented the accumulation of abnormally phosphorylated and fragmented TAR DNA-binding protein-43 (TDP-43) in spinal cord, a protein pivotal to the development of ALS. CuII(atsm) therefore represents a potential new class of neuroprotective agents targeting multiple major disease pathways of motor neurons with therapeutic potential for ALS.
Collapse
Affiliation(s)
- Cynthia P W Soon
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Paul S Donnelly
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Bradley J Turner
- Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010; Florey Neuroscience Institutes, The University of Melbourne, Parkville, Victoria 3010
| | - Lin W Hung
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Peter J Crouch
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Nicki A Sherratt
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Jiang-Li Tan
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010
| | - Nastasia K-H Lim
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Linh Lam
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Laura Bica
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010
| | - SinChun Lim
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - James L Hickey
- School of Chemistry, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Julia Morizzi
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Andrew Powell
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - David I Finkelstein
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Janetta G Culvenor
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Colin L Masters
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - James Duce
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010
| | - Anthony R White
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010
| | - Kevin J Barnham
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria 3010.
| | - Qiao-Xin Li
- Department of Pathology, The University of Melbourne, Parkville, Victoria 3010; Mental Health Research Institute, The University of Melbourne, Parkville, Victoria 3010; Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010.
| |
Collapse
|